STEP-HFpEF
Prespecified pooled analysis of the STEP-HFpEF program shows once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
STEP-HFpEF: Semaglutide and NT-proBNP in Obesity-Related HFpEF
A prespecified secondary analysis of the STEP-HFpEF programme found that semaglutide 2.4 mg lowered NT-proBNP and produced larger health-status gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
AI Scoring in Semaglutide NASH Trial
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
FLOW Trial: Semaglutide and Baseline SGLT2 Inhibitor Use in Type 2 Diabetes with CKD
A prespecified FLOW subgroup analysis tested whether semaglutide's kidney and cardiovascular benefit held with or without baseline SGLT2 inhibitor use in type 2 diabetes and CKD. PICO summary and expert commentary.
STEP-HFpEF: Semaglutide Efficacy by Sex
Prespecified secondary analysis of the pooled STEP-HFpEF trials finds semaglutide 2.4 mg improves heart failure symptoms similarly in women and men, with greater weight loss in women. PICO summary and expert commentary.
Oral Semaglutide Pharmacokinetics in Healthy Chinese Adults: A Phase 1 Trial
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
Semaglutide and Long-Term Weight Loss in Obesity Without Diabetes: SELECT Anthropometric Analysis
A prespecified analysis of the SELECT trial shows once-weekly semaglutide produced a placebo-subtracted weight reduction of 10.2% sustained to 208 weeks in adults with cardiovascular disease and overweight or obesity but without diabetes. PICO summary and expert commentary.
SELECT: Semaglutide and Kidney Outcomes in Obesity
A pre-specified analysis of the SELECT trial assessing whether once-weekly semaglutide 2.4 mg improves kidney outcomes in adults with overweight or obesity and cardiovascular disease, without diabetes. PICO summary and expert commentary.
Semaglutide and NYHA Functional Class in Obesity-Related HFpEF (STEP-HFpEF Program)
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide and Kidney Health
In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.